ChiCTR2500110896 版本V1.0 版本创建时间2025/10/22 14:29:40 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500110896 

最近更新日期:

Date of Last Refreshed on:

2025-10-22 14:29:29 

注册时间:

Date of Registration:

2025-10-22 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

急性冠脉综合征患者介入治疗术后早期心肺运动试验评估时机的探索

Public title:

Timing of cardiopulmonary exercise test after percutaneous coronary intervention in patients with acute coronary syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

急性冠脉综合征患者介入治疗术后早期心肺运动试验评估时机的探索

Scientific title:

Timing of cardiopulmonary exercise test after percutaneous coronary intervention in patients with acute coronary syndrome

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王国栋 

研究负责人:

王国栋 

Applicant:

Wang Guodong 

Study leader:

Wang Guodong 

申请注册联系人电话:

Applicant telephone:

+86 131 4618 1801

研究负责人电话:

Study leader's
telephone:

+86 131 4618 1801

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangguodong@ccmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

wangguodong@ccmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市丰台区角门北路10号

研究负责人通讯地址:

北京市丰台区角门北路10号

Applicant address:

Cardiovascular Medicine Department, China Rehabilitation Research Center, Beijing Bo’ai Hospital, 10 Jiaomen North Road, Fengtai District, Beijing, China

Study leader's address:

Cardiovascular Medicine Department, China Rehabilitation Research Center, Beijing Bo’ai Hospital, 10 Jiaomen North Road, Fengtai District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国康复研究中心

Applicant's institution:

China Rehabilitation Research Center

研究负责人所在单位:

中国康复研究中心

Affiliation of the Leader:

China Rehabilitation Research Center

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-047-2

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国康复研究中心医学伦理委员会

Name of the ethic committee:

Ethic committee of China Rehabilitation Research Center

伦理委员会批准日期:

Date of approved by ethic committee:

2023-06-26 00:00:00

伦理委员会联系人:

孟丽君

Contact Name of the ethic committee:

Meng Lijun

伦理委员会联系地址:

北京市丰台区角门北路10号

Contact Address of the ethic committee:

10 Jiaomen North Road, Fengtai District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8758 9667

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国康复研究中心

Primary sponsor:

China Rehabilitation Research Center

研究实施负责(组长)单位地址:

北京市丰台区角门北路10号

Primary sponsor's address:

Cardiovascular Medicine Department, China Rehabilitation Research Center, Beijing Bo’ai Hospital, 10 Jiaomen North Road, Fengtai District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京博爱医院

具体地址:

北京市丰台区角门北路10号

Institution
hospital:

Beijing Bo’ai Hospital

Address:

10 Jiaomen North Road, Fengtai District, Beijing, China

经费或物资来源:

中国康复研究中心

Source(s) of funding:

China Rehabilitation Research Center

研究疾病:

心脏病康复  

Target disease:

Cardiac rehabilitation

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究目的旨在探讨ACS住院患者PCI术后早期行CPET评估的时机及安全性,同时明确早期启动以运动训练为主的心脏康复对ACS-PCI术后患者的预后。  

Objectives of Study:

To explore the timing and safety of early CPET evaluation for ACS hospitalized patients after PCI, and to clarify the prognosis of ACS-PCI patients after early initiation of cardiac rehabilitation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)年龄≥18岁; (2)确诊ACS患者; (3)行PCI治疗; (4)受试者口头确认理解研究的风险、获益以及受试者本人和合法委托人签署知情同意书。

Inclusion criteria

1. Age >= 18 years old; 2.Confirmed ACS patients; 3.Undergo PCI treatment; 4.The subjects verbally confirm their understanding of the risks and benefits of the study, as well as the informed consent form signed by the subjects themselves and their legitimate client.

排除标准:

(1)心源性休克; (2)严重介入并发症(大出血、假性动脉瘤、下肢血肿); (3)恶性室性心律失常; (4)不愿意或不能完成本研究者。

Exclusion criteria:

1.Cardiogenic shock; 2. Serious interventional complications (massive bleeding, pseudoaneurysm, lower limb hematoma); 3. Malignant ventricular arrhythmias; 4. Those who are unwilling or unable to complete this study.

研究实施时间:

Study execute time:

From 2023-08-01 00:00:00 To 2026-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-08-23 00:00:00 To 2025-11-30 00:00:00

干预措施:

Interventions:

组别:

早期CPET干预组≤1周

样本量:

165

Group:

Early CPET group<=1w

Sample size:

干预措施:

规律运动训练

干预措施代码:

Intervention:

Regular physical exercise

Intervention code:

组别:

早期CPET干预组>1周

样本量:

165

Group:

Early CPET group>1w

Sample size:

干预措施:

常规康复训练

干预措施代码:

Intervention:

Routine rehabilitation training

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国康复研究中心(北京博爱医院) 

单位级别:

三甲 

Institution
hospital:

China Rehabilitation Research Center(Beijing Bo’ai Hospital)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

安全性指标

指标类型:

主要指标

Outcome:

Safety metrics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主要心血管事件

指标类型:

次要指标

Outcome:

Major cardiovascular events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

首先将行PCI治疗的ACS患者由独立机构运行的网络随机程序按1:1随机分为2组,常规CPET评估组(>1周),早期CPET评估组(≤1周),比较两组安全性指标(生命体征、CPET完成率及并发症、RER达标率、心肌酶、心电图、心脏彩超等指标)。 其次将每组患者由独立机构运行的网络随机程序按1:1随机分配至规律运动训练组和常规康复训练组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Firstly, ACS patients undergoing PCI treatment were randomly divided into two groups using a 1:1 network randomization program run by an independent institution. The conventional CPET evaluation group (>1 week) and the early CPET evaluation group (≤ 1 week) were compared in terms of safety indicators (vital signs, CPET completion rate and complications, RER compliance rate, myocardial enzymes, electrocardiogram, cardiac ultrasound, and other indicators). Secondly, each group of patients was randomly assigned to a regular exercise training group and a routine rehabilitation training group in a 1:1 ratio using a network randomization program run by an independent institution.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后一年内,国家生物信息中心 https://ngdc.cncb.ac.cn/gsa

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within one year of publication, China Nation center for Bioinformation https://ngdc.cncb.ac.cn/gsa.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表及数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and Database

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-10-22 14:29:29